Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial-March 2024-www.financetom.com

Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial

Mar 25, 2024 3:59 AM

March 25 (Reuters) - Axsome Therapeutics ( AXSM ) said

on Monday its therapy for a sleep disorder met the main goal of

a late-stage study.

(Reporting by Puyaan Singh; Editing by Sriraj Kalluvila)

Previous page： Microbix Biosystems Partners with Sekisui Diagnostics to Support COVID/Flu Tests Next page： Polestar Q3 Loss Widens, Revenue Rises; Shares Down Pre-Bell

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Microbix Biosystems Partners with Sekisui Diagnostics to Support COVID/Flu Tests

Nov 12, 2025

07:32 AM EST, 11/12/2025 (MT Newswires) -- Microbix Biosystems ( MBXBF ) said Wednesday Sekisui Diagnostics will use Microbix's third-party quality assessment products to support the U.S. commercialization of Sekisui's molecular point-of-care assay for diagnosis of COVID/Flu A/Flu B. The test is being made available in the U.S. under an Emergency-Use Authorization from the U.S. Food and Drug Administration, a...

Polestar Q3 Loss Widens, Revenue Rises; Shares Down Pre-Bell

Nov 12, 2025

07:35 AM EST, 11/12/2025 (MT Newswires) -- Polestar Automotive (PSNY) reported a Q3 net loss Wednesday of $365.3 million, widening from a loss of $322.8 million a year earlier. A single analyst polled by FactSet expected a loss of $364.6 million. Revenue for the quarter ended Sept. 30 was $748 million, up from $550 million a year earlier. A single...

Alkermes' narcolepsy drug meets main goal in a mid-stage trial

Nov 12, 2025

Nov 12 (Reuters) - Alkermes ( ALKS ) said on Wednesday its experimental narcolepsy drug met the main goals in a mid-stage study. (Reporting by Kamal Choudhury in Bengaluru; Editing by Anil D'Silva) ...

Virtus Investment Partners Reports Lower Preliminary Assets Under Management for October

Nov 12, 2025

07:36 AM EST, 11/12/2025 (MT Newswires) -- Virtus Investment Partners ( VRTS ) said Wednesday preliminary assets under management totaled $166.20 billion as of Oct. 31, down from $169.33 billion a month earlier. The company said the decline was attributed to market performance and net outflows in US retail funds, retail separate accounts, and institutional accounts, partially offset by positive...